Original Article
Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter
N Engl J Med 2007; 357:987-999September 6, 2007
- Abstract
Background
Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects. Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects.
Methods
In two identical multicenter, double-blind, randomized trials, one conducted in Europe (ClinicalTrials.gov number, NCT00259428) and one conducted in the United States, Canada, Australia, South Africa, and Argentina (termed the non-European trial, NCT00259376), we evaluated the efficacy of dronedarone, with 828 patients receiving 400 mg of the drug twice daily and 409 patients receiving placebo. Rhythm was monitored transtelephonically on days 2, 3, and 5; at 3, 5, 7, and 10 months; during recurrence of arrhythmia; and at nine scheduled visits during a 12-month period. The primary end point was the time to the first recurrence of atrial fibrillation or flutter.
Results
In the European trial, the median times to the recurrence of arrhythmia were 41 days in the placebo group and 96 days in the dronedarone group (P=0.01). The corresponding durations in the non-European trial were 59 and 158 days (P=0.002). At the recurrence of arrhythmia in the European trial, the mean (±SD) ventricular rate was 117.5±29.1 beats per minute in the placebo group and 102.3±24.7 beats per minute in the dronedarone group (P<0.001); the corresponding rates in the non-European trial were 116.6±31.9 and 104.6±27.1 beats per minute (P<0.001). Rates of pulmonary toxic effects and of thyroid and liver dysfunction were not significantly increased in the dronedarone group.
Conclusions
Dronedarone was significantly more effective than placebo in maintaining sinus rhythm and in reducing the ventricular rate during recurrence of arrhythmia.
Media in This Article
Figure 1
Enrollment and Outcomes in the European and the Non-European Trials.Figure 2
Kaplan–Meier Cumulative Incidence of the Adjudicated First Recurrence of Atrial Fibrillation or Flutter.Article Activity
- Article
Atrial fibrillation is the most common arrhythmia requiring hospitalization.1,2 Although arrhythmia-related symptoms and thromboembolic strokes are significantly reduced by anticoagulation therapy and rate control, sinus rhythm is often associated with improvement in exercise capacity and quality of life.3 Therefore, restoration and maintenance of sinus rhythm remain major therapeutic goals for patients with atrial fibrillation.3-6
Amiodarone is an especially potent atrial antifibrillatory agent,7 but it induces potentially serious side effects in some patients.7-10 Thus, compounds that are devoid of such effects but that retain the antiarrhythmic potential of amiodarone are therapeutically desirable.7,11 Dronedarone is a benzofuran derivative with an electropharmacologic profile closely resembling that of amiodarone12-20 but with structural differences intended to eliminate the effects of amiodarone on thyroid and pulmonary functions.17,18 In addition, the elimination half-life of dronedarone is 1 to 2 days, as compared with 30 to 55 days for amiodarone.20 We investigated the hypothesis that dronedarone is superior to placebo for maintaining sinus rhythm after electrical, pharmacologic, or spontaneous conversion from atrial fibrillation or atrial flutter.
Methods
Study Design
The European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm (EURIDIS, NCT00259428) and the American–Australian–African Trial with Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS, NCT00259376) were two identical, placebo-controlled, multicenter, double-blind, parallel-group trials sponsored by Sanofi-Aventis. The European trial was conducted in 12 European countries, and the non-European trial was conducted in the United States, Canada, Australia, South Africa, and Argentina.
The study protocols were approved by the human-research review boards at each participating institution. A single common steering committee designed the studies and the data analysis plans in collaboration with the sponsor. An independent data and safety monitoring board oversaw the safety of patients. All data-management activities were the responsibility of the sponsor. Data entry, verification, and validation were performed with the use of standard computer software (Clintrial 4.3), and data were stored in an Oracle database on a Sun Solaris computer. At study termination, the database was locked and transferred to the biostatistics department at Sanofi-Aventis for analysis. The academic investigators had independent access to the raw data. Dr. Singh, who wrote the manuscript with input from the other steering-committee members and from Sanofi-Aventis personnel, vouches for the accuracy and completeness of the data and the analysis.
Patients
Patients qualifying for enrollment were of either sex and at least 21 years of age, had had at least one episode of atrial fibrillation (as seen on electrocardiography) in the preceding 3 months, and were in sinus rhythm for at least 1 hour before randomization. Excluded from the study were patients with permanent atrial fibrillation (i.e., a duration of at least 12 months); women who could become pregnant and who were not using birth control; patients who had had torsades de pointes; patients with persistent bradycardia of less than 50 beats per minute, a PR interval of 0.28 second or more on electrocardiography, second-degree (or higher) atrioventricular block, and clinically significant sinus-node disease without an implanted pacemaker; patients who were taking class I or III antiarrhythmic agents; patients with New York Heart Association class III or IV congestive heart failure; and patients with a serum creatinine level of 1.7 mg per deciliter (150 μmol per liter) or more, severe electrolyte abnormalities, and clinically significant hepatic, pulmonary, endocrine, or other disorders associated with atrial fibrillation. Previous treatment with amiodarone was permitted, and patients who had received the drug could be enrolled immediately after its discontinuation. Written informed consent was obtained from all patients.
Baseline Evaluation, Randomization, and Therapy
All study patients underwent a baseline evaluation that included a medical history, symptom review, cardiovascular examination, assessment of vital signs, 12-lead electrocardiography, chest radiography, and laboratory tests, including a complete blood count and tests of serum electrolytes, urea, creatinine, and cholesterol and thyroid and liver function. Left atrial size and left ventricular ejection fraction were determined by two-dimensional echocardiography. Eligible patients who were not in sinus rhythm during screening could be enrolled if they underwent successful cardioversion and remained in sinus rhythm for at least 1 hour.
After a 7-day screening period, eligible patients were randomly assigned in a 2:1 ratio to receive either 400 mg of oral dronedarone twice daily or a matching placebo. A stochastic randomization procedure suggested by Pocock and Simon21 and revised by Freedman and White22 was used. On the first day of the study, symptoms were evaluated, vital signs were assessed, the assigned study drug was administered, and 12-lead electrocardiography was performed.
Follow-up
We scheduled follow-up visits that included a review of symptoms, assessment of vital signs, and performance of electrocardiography on days 7, 14, and 21 and at 2, 4, 6, 9, and 12 months. The above-mentioned blood tests were repeated on day 21 and at months 4, 9, and 12. Chest radiography was repeated in the case of pulmonary symptoms.
All enrolled patients were given a transtelephonic electrocardiographic monitor and were instructed in its use. Patients transmitted electrocardiograms on days 2, 3, and 5; at months 3, 5, 7, and 10; and whenever they had symptoms. On each occasion, two electrocardiograms were recorded approximately 10 minutes apart and were evaluated at a central core laboratory (MDS Pharma Services, Paris) by investigators who were unaware of study-group assignments to confirm the recurrence of atrial fibrillation. Each time an electrocardiogram was recorded, the patient was contacted to confirm the occurrence of one or more of the following symptoms: palpitations, dizziness, fatigue, chest pain, and dyspnea. Reported symptoms were taken into account if they were accompanied by atrial fibrillation. If oral anticoagulation therapy was administered, the international normalized ratio was monitored locally.
Study End Points
The primary end point was the time from randomization to the first documented recurrence of atrial fibrillation, defined as an episode lasting for at least 10 minutes and confirmed by two consecutive recordings taken 10 minutes apart on 12-lead electrocardiography or transtelephonic monitoring. The main secondary end points were symptoms related to atrial fibrillation during recordings of 12-lead electrocardiography or transtelephonic monitoring and the mean ventricular rate during the first recurrence.
Statistical Analysis
The hypothesis for determining the number of patients needed for the study was derived from data from efficacy trials of antiarrhythmic drugs for the treatment of atrial fibrillation.23-25 It was presumed that 60% of patients in the placebo group would have a recurrence of arrhythmia within 12 months; a relative decrease in this rate of at least 25% was expected in the dronedarone group (i.e., a 45% recurrence rate).
With a sample size of 552 patients (368 in the dronedarone group and 184 in the placebo group), each trial would have a power of 90% to detect a between-group difference, assuming a 20% dropout rate and a 1-year follow-up period. The primary analysis was performed according to a modified intention-to-treat principle, with all randomized patients who received at least one dose of a study drug included. A secondary on-treatment analysis was also performed. A two-sided Fisher's exact test was used for qualitative measures. The event-free probability curves were estimated by the nonparametric Kaplan–Meier technique, with 95% confidence intervals. A standard log-rank technique was used to test the null hypothesis of identical Kaplan–Meier curves in the two study groups. All reported P values are two-sided, and P values of less than 0.05 were considered to indicate statistical significance.
Results
Patients
In the European trial, 680 patients were screened, and 612 were randomly assigned to study groups to receive treatment (411 to the dronedarone group and 201 to the placebo group). In the non-European trial, 731 patients were screened, and 625 were randomly assigned to receive treatment (417 to the dronedarone group and 208 to the placebo group). Three patients in the European trial and four in the non-European trial did not receive a study drug (Figure 1Figure 1
Enrollment and Outcomes in the European and the Non-European Trials.).Table 1Table 1
Baseline Characteristics of the Study Patients. presents the baseline characteristics of the patients in the European and non-European trials, individually and combined. The mean age of all patients was 63 years, and 69% were men; 41% had structural heart disease. There were 60 patients (10%) with atrial flutter in the European trial and 71 (11%) in the non-European trial. In the European trial, 67 patients in the dronedarone group and 25 in the placebo group discontinued the study prematurely; in the non-European trial, the corresponding numbers were 81 and 36.Primary End Point
In the European trial, according to the modified intention-to-treat analysis, the median times from randomization to a documented recurrence of atrial fibrillation were 96 days in the dronedarone group and 41 days in the placebo group. At 12 months, 67.1% of patients in the dronedarone group and 77.5% of patients in the placebo group had had a recurrence of atrial fibrillation (hazard ratio for the dronedarone group, 0.78; 95% confidence interval [CI], 0.64 to 0.96; P=0.01) (Table 2Table 2
Study End Points.). On-treatment analysis of the same population had similar results (P=0.01).In the non-European trial, according to a modified intention-to-treat analysis, the median times from randomization to a documented recurrence of atrial fibrillation were 158 days in the dronedarone group and 59 days in the placebo group. At 12 months, 61.1% of patients in the dronedarone group and 72.8% of patients in the placebo group had had a recurrence of atrial fibrillation (hazard ratio, 0.73; 95% CI, 0.59 to 0.89; P=0.002) (Table 2). The results of on-treatment analysis were confirmatory (P=0.002).
For the two trials combined, the median times to a documented recurrence of atrial fibrillation were 116 days in the dronedarone group and 53 days in the placebo group. At 12 months, the rates of recurrence were 64.1% in the dronedarone group and 75.2% in the placebo group (hazard ratio, 0.75; 95% CI, 0.65 to 0.87; P<0.001) (Table 2). Figure 2Figure 2
Kaplan–Meier Cumulative Incidence of the Adjudicated First Recurrence of Atrial Fibrillation or Flutter. shows the Kaplan–Meier cumulative incidence curves for the adjudicated first recurrence in patients in the European trial and the non-European trial, separately and combined. The association of dronedarone with a reduction in the risk of recurrence of atrial fibrillation, as compared with placebo, was consistent for a series of clinically important subgroups (Figure 3Figure 3
Hazard Ratio for the Adjudicated First Recurrence of Atrial Fibrillation or Flutter, According to Selected Baseline Characteristics.).A separate preplanned analysis excluded patients with a study-drug exposure of less than 5 days before the occurrence of the primary end point (either because the patient discontinued treatment within 5 days or because atrial fibrillation recurred within 5 days). In the European trial, this analysis showed that patients in the dronedarone group had a reduction in the risk of adjudicated recurrence of 29% from day 5 to 12 months after randomization, as compared with those in the placebo group (P=0.006 by the log-rank test). In the non-European trial, the reduction was 26% (P=0.02 by the log-rank test) (Table 2).
Heart Rate and QT Interval in Sinus Rhythm
In the combined European and non-European trials, the effects of dronedarone, as compared with those of placebo, on the mean heart rate, QT interval, and QT interval corrected for heart rate (QTc) were investigated in preplanned analyses (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). As compared with baseline values, in the dronedarone group, heart rate was reduced by 6.8%, the QT interval was prolonged by 23.4 msec, and the QTc interval was prolonged by 9.0 msec (P<0.001 for all comparisons with the placebo group), without significant effects on the QRS duration.
Ventricular Rate at First Recurrence
In both trials, ventricular rates during the recurrence of atrial fibrillation were evaluated in preplanned analyses. In the European trial, the mean (±SD) ventricular rate during the first adjudicated recurrence was 102.3±24.7 beats per minute in the dronedarone group and 117.5±29.1 beats per minute in the placebo group (P<0.001). The corresponding numbers for the non-European trial were 104.6±27.1 beats per minute in the dronedarone group and 116.6±31.9 beats per minute in the placebo group (P<0.001) (Table 2).
Symptomatic First Recurrence
In another preplanned analysis, the rates of symptomatic recurrence of atrial fibrillation were compared between the study groups in each trial. The majority of documented first recurrences were symptomatic, and the pattern of symptoms did not differ between the dronedarone group and the placebo group. In the European trial, 37.1% of patients in the dronedarone group and 47.5% of those in the placebo group had symptomatic recurrences (P=0.006 by the log-rank test). In the non-European trial, symptomatic recurrences occurred in 38.3% of patients in the dronedarone group and 44.5% of those in the placebo group (P=0.02 by the log-rank test). The corresponding numbers for the pooled data were 37.7% and 46.0% (P<0.001 by the log-rank test) (Table 2). The Prentice cumulative incidence curves26 for a symptomatic first recurrence for the pooled data are shown in the Supplementary Appendix.
Hospitalization or Death
In the European Trial, a post hoc analysis revealed that 21.2% of patients in the dronedarone group had been hospitalized or had died at 12 months, as compared with 32.0% of those in the placebo group (hazard ratio, 0.66; 95% CI, 0.47 to 0.93; P=0.02). In the non-European trial, 24.5% of patients in the dronedarone group had been hospitalized or had died, as compared with 29.8% of those in the placebo group (hazard ratio, 0.80; 95% CI, 0.56 to 1.14; P=0.22). The corresponding numbers in the combined analysis were 22.8% and 30.9% (hazard ratio, 0.73; 95% CI, 0.57 to 0.93; P=0.01) (Table 2).
Adverse Events
Table 3Table 3
Selected Adverse Events and Laboratory Abnormalities. shows the incidence of selected adverse events in the two study groups. Most of these specific adverse events are shown because they include many of the known side effects of amiodarone. In addition, there was a higher incidence of elevated serum creatinine levels in the dronedarone group than in the placebo group (2.4% vs. 0.2%, P=0.004).In addition to the events listed in Table 3, one patient in the dronedarone group received the diagnosis of interstitial lung disease, which was reported after the patient had completed the 1-year follow-up. This patient also had mitral-valve disease and a history of congestive heart failure and had had a viral infection during the week preceding the report of the diagnosis. The pulmonary findings subsequently resolved without sequelae. A second patient in the dronedarone group was reported to have pulmonary fibrosis, which on further investigation and blinded radiologic review had been present on chest radiography at baseline. Ventricular arrhythmias occurred infrequently in both study groups; no episodes of torsades de pointes were reported.
Discussion
The European trial and the non-European trial were large, double-blind, placebo-controlled trials, each comparing the efficacy of dronedarone with that of placebo for the maintenance of sinus rhythm in patients with atrial fibrillation. We found that dronedarone reduced the incidence of a first recurrence, as well as a symptomatic first recurrence, within 12 months after randomization. Dronedarone also significantly reduced the ventricular rate during the recurrence of arrhythmia. In addition, in a post hoc analysis, dronedarone significantly reduced the rate of hospitalization or death.
In both the European and non-European trials, dronedarone prolonged the time to the recurrence of atrial fibrillation by a factor of more than 2, as compared with placebo. This finding is consistent with the drug's propensity for markedly prolonging the atrial effective refractory period18,27 by inducing multiple ion-channel blockade.15 However, the effectiveness of dronedarone in maintaining sinus rhythm in atrial fibrillation cannot be reliably compared with that of amiodarone or sotalol on the basis of these data. The latter agents have been evaluated in studies that may have differed markedly from our trials with respect to the trial design, study population, and pattern of atrial fibrillation (paroxysmal or persistent).3,24,28,29 In our trials, patients were in sinus rhythm at the time of randomization, but the trial design did not permit a clear distinction between patients who had persistent atrial fibrillation and those with paroxysmal atrial fibrillation. It is likely that most of the patients in our trials who did not require direct-current cardioversion during the 5 days preceding randomization (71%) had paroxysmal atrial fibrillation or flutter. The results of the subgroup analyses underscore the consistent effectiveness of dronedarone in maintaining sinus rhythm in patients with atrial fibrillation encompassing a wide range of covariates.
In our trials, the effectiveness of 400 mg of dronedarone twice daily in maintaining sinus rhythm without major prolongation of either the QT or the QTc interval suggests a measure of atrial selectivity of the drug action, as reported in studies involving rabbit ventricular and atrial cells.17,18 Amiodarone and dronedarone both limit the risk of torsades de pointes by attenuating after-depolarization activity in the M cell and Purkinje fiber activity30-38 in the ventricular myocardium. In the case of amiodarone, torsades de pointes is rare,32,33 and to date an unequivocal case of torsades induced by dronedarone has not been noted despite the lengthening of the QT and QTc intervals by 23 and 9 msec, respectively, in our combined trials.
In neither of the trials did we directly compare dronedarone with amiodarone. Therefore, we cannot be certain that the efficacy of dronedarone is similar to that of amiodarone, nor can we state with certainty that the rate of adverse events is significantly lower. On the basis of experience with amiodarone in other trials, our findings suggest these conclusions, but a definitive answer will require a trial that directly compares the two drugs. Furthermore, the low rate of adverse events (especially pulmonary toxic effects) may be explained in part by the relatively short duration of our trials and by the fact that chest radiography and assessment of pulmonary function were not performed unless symptoms were present.
As in many other trials examining the efficacy of treatments for atrial fibrillation, it is likely that we were not able to detect every episode of recurrent arrhythmia in our study patients. Follow-up electrocardiograms were obtained at frequent intervals and in the case of symptoms. The fact that the majority of first documented recurrences were symptomatic strongly suggests that not all episodes were detected, since the majority of episodes of atrial fibrillation in the general population may be asymptomatic. Continuous monitoring of all study patients over the long term was beyond the scope of these trials and typically has not been considered essential for the interpretation of such studies.
A previous study, the Antiarrhythmic Trial with Dronedarone in Moderate to Severe Congestive Heart Failure Evaluating Morbidity Decrease (ANDROMEDA), was discontinued early because an interim safety analysis suggested a potential increase in the risk of death with dronedarone therapy. The discontinued trial involved patients with moderate-to-severe congestive heart failure and ventricular dysfunction, and thus investigated a different (and higher-risk) population than the patients we studied. In our trials, the rates of death from any cause and sudden death in the dronedarone group did not differ significantly from those in the placebo group. Nonetheless, the experience with the ANDROMEDA trial indicates that dronedarone may be associated with an increased risk of death in patients with advanced congestive heart failure and that the drug should not be used in such patients until appropriate data are gathered.
In conclusion, our trials showed that the rates of the first recurrence of atrial fibrillation and of the first symptomatic recurrence at 1 year were significantly reduced with dronedarone, as compared with placebo. Dronedarone also reduced the ventricular rate in atrial fibrillation during recurrences of arrhythmia. The available data are not directive with respect to the rates of adverse effects, as compared with those of amiodarone.
Supported by Sanofi-Aventis.
Dr. Singh reports receiving consulting and lecture fees from CV Therapeutics, Sanofi-Aventis, GlaxoSmithKline, Astellas, and Procter & Gamble Pharmaceuticals; Dr. Hohnloser, consulting fees from Sanofi-Aventis, St. Jude Medical, Boehringer Ingelheim, Procter & Gamble Pharmaceuticals, and Solvay Pharmaceuticals and lecture fees from Sanofi-Aventis and St. Jude Medical; Dr. Connolly, consulting and lecture fees from Sanofi-Aventis and grant support from Sanofi-Aventis, Boehringer Ingelheim, and St. Jude Medical; Dr. Crijns, consulting fees from Sanofi-Aventis, AstraZeneca, Cardiome, and Meda Pharma, lecture fees from Sanofi-Aventis, AstraZeneca, St. Jude Medical, and Meda Pharma, and grant support from Medtronic, St. Jude Medical, and Sanofi-Aventis; Dr. Roy, consulting and lecture fees from Sanofi-Aventis, Astellas, and Cardiome and grant support from the Canadian Institutes of Health Research; Dr. Kowey, consulting fees from Sanofi-Aventis, Reliant, Cardiome, Astellas, Procter & Gamble Pharmaceuticals, and Solvay Pharmaceuticals and lecture fees from Sanofi-Aventis; Dr. Capucci, consulting fees from CV Therapeutics and St. Jude Medical and lecture fees from Sanofi-Aventis, Meda Pharma, and Pfizer; Dr. Radzik, being employed by Sanofi-Aventis and having equity interest in the company; and Dr. Aliot, consulting and lecture fees from Sanofi-Aventis, Meda Pharma, and Sorin-Ela. No other potential conflict of interest relevant to this article was reported.
Source Information
From the Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA — both in Los Angeles (B.N.S.); the University of Hamilton, Hamilton, ON, Canada (S.J.C.); the University of Maastricht, Maastricht, the Netherlands (H.J.G.M.C.); the University of Montreal, Montreal (D. Roy); Lankenau Hospital and Institute of Medical Research, Philadelphia (P.R.K.); Ospedale Clinical, Taverna, Italy (A.C.); Sanofi-Aventis, Paris (D. Radzik); Hôpital Central, Nancy, France (E.M.A.); and Goethe University, Frankfurt, Germany (S.H.H.).
Address reprint requests to Dr. Singh at Veterans Affairs Greater Los Angeles Healthcare System, Cardiology Division, 11301 Wilshire Blvd., Los Angeles, CA 90073, or at bsingh@ucla.edu.
Members of the European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm (EURIDIS) and American–Australian–African Trial with Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS) are listed in the Appendix.
Appendix
The following authors and other investigators participated in the European trial and the non-European trial: Steering Committee: B.N. Singh (chair), E. Aliot, A. Capucci, S.J. Connolly, H.J.G.M. Crijns, S. Hohnloser, P. Kowey, L.D. Roy, and D. Radzik. Data and Safety Monitoring Board: Lyon, France — A. Leizorovicz (chair); London — J. Camm; Miami — R. Myerburg.
European trial: Belgium — J. Boland, P. Brugada, L. De Roy, G. Mairesse; Czech Republic — J. Bytesnik, M. Herold, J. Hradec, B. Semrad; France — J. Davy, P. Defaye, P. Djiane, S. Kacet, A. Leenhardt, E. Quiring; Germany — D. Andresen, G. Baumann, S. Felix, E. Hoffmann, S.H. Hohnloser, J. Kiehn, C. Karle, T. Lewalter, V. Mitrovic, A. Schirdewan, S. Spitzer; Hungary — M. Mezofi, L. Regos, K. Simon, J. Tomcsanyi; Italy — P. Rizzon, J. Salerno-Uriarte, M. Santini, P. Schwartz; Poland — T. Kawka-Urbanek, T. Marczyk, P. Miekus, W. Musial, G. Opolski, M. Piepiorka, W. Tracz, M. Trusz-Gluza; Spain — J. Alzueta-Rodriquez, G. Baron, P. Blanch, C. Moro, A. Salvador, J. Vilaplana; the Netherlands — A. Anneveldt, F.A.L.E. Bracke, C. Burgersdijk, H.J.G.M. Crijns, J.A. Kragten, D.J.A. Lok, J.G. Meeder, L.H. Savalle, A.J.M. Timmermans, I.C. Van Gelder, L.H.J. Van Kempen, E.P. Viergever; Denmark: P. Grande, B. Sigurd, C. Torp-Pedersen; Finland: H. Huikuri, K. Peuhkurinen, A. Ylitalo; United Kingdom — E. Rowland. Non-European trial: Argentina — M. Elizari, A. Gambarte, J. Gonzalez, J. Krauss, J. Vallejos; Australia — J. Amerena, J. Counsell, M. Davis, J. Hill, J. Leitch, J. Sampson, B. Singh, D. Whalley, A. Whelan; Canada — P. Auger, J. Bedard, R. Bhargava, P. Bolduc, D. Borts, G. Boutros, J. Champagne, Y. Chan, L. Charles, S. Connolly, P. Costi, P. Dorian, C. Fortin, M. Green, S. Kouz, R. Leather, P. Ma, B. Mitchell, A. Mukherjee, D. Quimet, D. Roy, M. Senaratne, Z. Wulffhart; South Africa — S. Hardcastle, J. Du Toit, D. Milne, D. Naidoo, I. Obel, R. Scott-Millar, N. Van Der Merwe, H. Dutoit Theron; United States — W. Abraham, C. Kuo, M. Berk, R. Bryg, M. Carlson, J. Mackall, C. Chen, A. Chu, H. Colfer, G. Crossley, L. Dreifus, K. Ellenbogen, G. Emlein, R. Falk, G. Feld, C. Fellows, R. Filart, J. Fleischhauer, D. Gilligan, J. Glass, M. Goldberg, C. Goren, D. Gottlieb, G. Grewal, J. Herre, S. Hessen, A. Jacobson, S. Keim, S. Kim, R. Klein, M. Koren, P. Kowey, J. Krantzler, R. Leman, T. Lessmeier, L. Lewkowiez, B. McGovern, C. Albert, B. McLaurin, G. San, G. Naccarelli, I. Niazi, P. O'Neill, B. Peart, M. Platt, S. Promisloff, A. Quick, J. Reiffel, E. Roth, S. Rothbart, J. Sacco, B.N. Singh, N. Smiley, J. Steinberg, M. Tonkon, N. Vijay, K. Vijayaraghavan, P. Vijayaraman, H. Weiner, R. Weiss, B. Williamson, J. Baker, and G. Wong.
- References
References
1
Go AS ,Hylek EM ,Phillips KA , et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375
CrossRef | Web of Science | Medline2
Tsang TS ,Gersh BJ . Atrial fibrillation: an old disease, a new epidemic. Am J Med 2002;113:432-435
CrossRef | Web of Science | Medline3
Singh BN ,Singh SN ,Reda DJ , et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-1872
Full Text | Web of Science | Medline4
Nattel S ,Khairy P ,Roy D , et al. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field. Drugs 2002;62:2377-2397
CrossRef | Web of Science | Medline5
Singh BN . Atrial fibrillation: epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm. J Cardiovasc Pharmacol Ther 2003;8:Suppl 1:S13-S26
CrossRef | Medline6
Oral H ,Knight BP ,Tada H , et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 2002;105:1077-1081
CrossRef | Web of Science | Medline7
Nattel S ,Singh BN . Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol 1999;84:11R-19R
CrossRef | Web of Science | Medline8
Wyse DG ,Waldo AL ,DiMarco JP , et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833
Full Text | Web of Science | Medline9
Hohnloser SH ,Kuck KH ,Lilienthal J . Rhythm or rate control in atrial fibrillation -- Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-1794
CrossRef | Web of Science | Medline10
Van Gelder IC ,Hagens VE ,Bosker HA , et al. A comparison of rate control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840
Full Text | Web of Science | Medline11
Hodeige D ,Heyndrickx JP ,Chatelain P ,Manning A . SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoreceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol 1995;279:25-32
CrossRef | Web of Science | Medline12
Manning AS ,Bruyninckx C ,Ramboux J ,Chatelain P . SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995;26:453-461
CrossRef | Web of Science | Medline13
Finance O ,Manning A ,Chatelain P . Effect of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 1995;26:570-576
CrossRef | Web of Science | Medline14
Manning A ,Thisse V ,Hodeige D ,Richard J ,Heyndrickx JP ,Chatelain P . SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. J Cardiovasc Pharmacol 1995;25:252-261
CrossRef | Web of Science | Medline15
Gautier P ,Marion A ,Bertrand JP ,Tourneur Y ,Nisato D . Electrophysiological characteristics of dronedarone (SR 33589), a new amiodarone-like agent, in cardiac ventricular myocytes. Eur Heart J 1997;18:Suppl:269-27816
Rochetti M ,Bertrand JP ,Nisato D , et al. Cellular electrophysiological study of dronedarone, a new amiodarone-like agent, in guinea pig sino-atrial node. Arch Pharmacol 1998;358:R617-R61717
Sun W ,Sarma JSM ,Singh BN . Electrophysiological effects of dronedarone (SR 33589), a noniodinated benzofuran derivative in the rabbit heart: comparison with amiodarone. Circulation 1999;100:2276-2283
Web of Science | Medline18
Sun W ,Sarma JSM ,Singh BN . Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol 2002;39:677-684
CrossRef | Web of Science | Medline19
Sicouri S ,Moro D ,Celestino D ,Elizari MV . Dronedarone and amiodarone reduce transmural dispersion of repolarization in the canine heart. Fundam Clin Pharmacol 1999;13:Suppl 1:72S-72S20
Touboul P ,Brugada J ,Cappuci A ,Crijns HJ ,Edvardssom N ,Hohnloser SH . Dronedarone for prevention of atrial fibrillation: a dose ranging study. Eur Heart J 2003;24:1481-1487
CrossRef | Web of Science | Medline21
Pocock SJ ,Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975;31:103-115
CrossRef | Web of Science | Medline22
Freedman LS ,White SJ . On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trials. Biometrics 1976;32:691-694
CrossRef | Web of Science | Medline23
Roy D ,Talajic M ,Dorian P , et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342:913-920
Full Text | Web of Science | Medline24
Benditt DG ,Williams JH ,Jin J , et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol 1999;84:270-277
CrossRef | Web of Science | Medline25
Coplen SE ,Antman EM ,Berlin JA ,Hewitt P ,Chalmers TC . Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990;82:1106-1116[Erratum, Circulation 1991;83:714.]
CrossRef | Web of Science | Medline26
Kalbfleisch JD, Prentice RJ. The statistical analysis of failure time data. 2nd ed. New York: Wiley, 2002:247-77.
27
Wadhani N ,Sarma JSM ,Singh BN ,Radzik D ,Gaud C . Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions. J Cardiovasc Pharmacol Ther 2006;11:184-190
CrossRef | Web of Science | Medline28
Chun SH ,Sager PT ,Stevenson WG ,Nademanee K ,Middlekauff HR ,Singh BN . Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50
CrossRef | Web of Science | Medline29
Connolly SJ . Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100:2025-2034
Web of Science | Medline30
Singh BN ,Wadhani N . Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther 2004;9:Suppl 1:S85-S97
CrossRef | Medline31
Roden DM . Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022
Full Text | Web of Science | Medline32
Hohnloser SH ,Singh BN . Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6:920-936
CrossRef | Web of Science | Medline33
Hohnloser SH ,Klingenheben T ,Singh BN . Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-535
Web of Science | Medline34
Papp JG ,Nemeth M ,Krassoi I ,Mester L ,Hala O ,Varro A . Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fiber versus ventricular muscle. J Cardiovasc Pharmacol Ther 1996;1:287-296
Medline35
Sicouri S ,Moro S ,Litovsky S ,Elizari MV ,Antzelevitch C . Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 1997;8:1269-1279
CrossRef | Web of Science | Medline36
Antzelevitch C ,Shimizu W ,Yan GX , et al. The M cell: its contribution to the ECG and normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999;10:1124-1152
CrossRef | Web of Science | Medline37
Antzelevitch C ,Belardinelli L ,Wu L , et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004;9:Suppl 1:S65-S83
CrossRef | Medline38
Nattel S . The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999;10:272-282
CrossRef | Web of Science | Medline
- Citing Articles (178)
Citing Articles
1
Vincent E. Friedewald, Robert C. Kowal, Brian Olshansky, Clyde W. Yancy, William C. Roberts. (2012) The Editor's Roundtable: Medical Management of Atrial Fibrillation. The American Journal of Cardiology 109:4, 563-569
CrossRef2
Claire McKenna, Emma Maund, Muhammad Sarowar, David Fox, Matt Stevenson, Chris Pepper, Nerys Woolacott, Stephen Palmer. (2012) Dronedarone for the Treatment of Atrial Fibrillation. PharmacoEconomics 30:1, 35-46
CrossRef3
Manuel Anguita, Fernando Worner, Pere Domenech, Francisco Marín, Javier Ortigosa, Julián Pérez-Villacastín, Antonio Fernández-Ortiz, Angel Alonso, Angel Cequier, Josep Comín, Magda Heras, Manuel Pan, Javier Alzueta, Angel Arenal, Gonzalo Barón, Xavier Borrás, Ramón Bover, Mariano de la Figuera, Carlos Escobar, Miguel Fiol, Benito Herreros, José L. Merino, Lluis Mont, Nekane Murga, Alonso Pedrote, Aurelio Quesada, Tomás Ripoll, José Rodríguez, Martín Ruiz, Ricardo Ruiz. (2012) Nuevas evidencias, nuevas controversias: análisis crítico de la guía de práctica clínica sobre fibrilación auricular 2010 de la Sociedad Europea de Cardiología. Revista Española de Cardiología 65:1, 7-13
CrossRef4
Manuel Anguita, Fernando Worner, Pere Domenech, Francisco Marín, Javier Ortigosa, Julián Pérez-Villacastín, Antonio Fernández-Ortiz, Angel Alonso, Angel Cequier, Josep Comín, Magda Heras, Manuel Pan, Javier Alzueta, Angel Arenal, Gonzalo Barón, Xavier Borrás, Ramón Bover, Mariano de la Figuera, Carlos Escobar, Miguel Fiol, Benito Herreros, José L. Merino, Lluis Mont, Nekane Murga, Alonso Pedrote, Aurelio Quesada, Tomás Ripoll, José Rodríguez, Martín Ruiz, Ricardo Ruiz. (2012) New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation. Revista Española de Cardiología (English Edition) 65:1, 7-13
CrossRef5
Peter Milberg, Gerrit Frommeyer, Timo Uphaus, Dennis Kaiser, Nani Osada, Günter Breithardt, Lars Eckardt. (2012) Electrophysiologic Profile of Dronedarone on the Ventricular Level. Journal of Cardiovascular Pharmacology 59:1, 92-100
CrossRef6
Stefan H. Hohnloser. (2012) Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation. Clinical Cardiology 35:S1, S28-S32
CrossRef7
Chern-En Chiang, Shu Zhang, Hung Fat Tse, Wee Siong Teo, Razali Omar, Charn Sriratanasathavorn. (2012) Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation. International Journal of Cardiology
CrossRef8
James H. Lewis, David E. Kleiner. 2012. Hepatic injury due to drugs, herbal compounds, chemicals and toxins. , 645-760.
CrossRef9
Nicholas B. Norgard, Mazen S. Abu-Fadel. 2011. Cardiovascular Disease: In-Depth Look. .
CrossRef10
Connolly, Stuart J., Camm, A. John, Halperin, Jonathan L., Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Álvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B., Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S., Merino, Jose L., Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S., Sim, Kui-Hian, Stiles, Martin K., Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H., . (2011) Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine 365:24, 2268-2276
Full Text11
Gregory YH Lip, Hung Fat Tse, Deirdre A Lane. (2011) Atrial fibrillation. The Lancet
CrossRef12
Hana Hoyt, Aditya Bhonsale, Karuna Chilukuri, Fawaz Alhumaid, Matthew Needleman, David Edwards, Ashul Govil, Saman Nazarian, Alan Cheng, Charles A. Henrikson, Sunil Sinha, Joseph E. Marine, Ronald Berger, Hugh Calkins, David D. Spragg. (2011) Complications arising from catheter ablation of atrial fibrillation: Temporal trends and predictors. Heart Rhythm 8:12, 1869-1874
CrossRef13
Alena Shantsila, Gregory Y.H. Lip. (2011) Dronedarone. American Journal Cardiovascular Drugs 11:6, 355-356
CrossRef14
Nikolaos Dagres, Christos Varounis, Efstathios K. Iliodromitis, John P. Lekakis, Loukianos S. Rallidis, Maria Anastasiou-Nana. (2011) Dronedarone and the Incidence of Stroke in Patients with Paroxysmal or Persistent Atrial Fibrillation. American Journal Cardiovascular Drugs 11:6, 395-400
CrossRef15
Marc Cohen, Catalin Boiangiu. (2011) The Management of Patients with Atrial Fibrillation and Dronedarone’s Place in Therapy. Advances in Therapy 28:12, 1059-1077
CrossRef16
AVINASH R. KHITRI, ETIENNE M. ALIOT, ALESSANDRO CAPUCCI, STUART J. CONNOLLY, HARRY CRIJNS, STEFAN H. HOHNLOSER, PIOTR KULAKOWSKI, DENIS ROY, DAVID RADZIK, PETER R. KOWEY. (2011) Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter. Journal of Cardiovascular Electrophysiologyno-no
CrossRef17
J.-L. Pasquié, J. Thireau, J.-M. Davy, J.-Y. Le Guennec, S. Richard. (2011) Médicaments anti-arythmiques : Présent et futur. Archives of Cardiovascular Diseases Supplements 3:3, 236-243
CrossRef18
Gaetano Serviddio, Francesco Bellanti, Anna Maria Giudetti, Gabriele Vincenzo Gnoni, Nazzareno Capitanio, Rosanna Tamborra, Antonino Davide Romano, Maurizio Quinto, Maria Blonda, Gianluigi Vendemiale, Emanuele Altomare. (2011) Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radical Biology and Medicine 51:12, 2234-2242
CrossRef19
Pedram Kazemian, Gavin Oudit, Bodh I. Jugdutt. (2011) Atrial fibrillation and heart failure in the elderly. Heart Failure Reviews
CrossRef20
Nadzeya Kuzniatsova, Burak Pamukcu, Gregory YH Lip. (2011) Dronedarone (Multaq ® ) for the treatment of atrial fibrillation. Therapy 8:6, 681-689
CrossRef21
Jérôme Thireau, Jean-Luc Pasquié, Eric Martel, Jean-Yves Le Guennec, Sylvain Richard. (2011) New drugs vs. old concepts: A fresh look at antiarrhythmics. Pharmacology & Therapeutics 132:2, 125-145
CrossRef22
I. C. Van Gelder, L. M. Haegeli, A. Brandes, H. Heidbuchel, E. Aliot, J. Kautzner, L. Szumowski, L. Mont, J. Morgan, S. Willems, S. Themistoclakis, M. Gulizia, A. Elvan, M. D. Smit, P. Kirchhof. (2011) Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 13:11, 1517-1525
CrossRef23
Cen Xie, Shilei Yang, Dafang Zhong, Xiaojian Dai, Xiaoyan Chen. (2011) Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study. Journal of Chromatography B 879:28, 3071-3075
CrossRef24
, Thomas Meinertz, Wilhelm Kirch, Ludger Rosin, David Pittrow, Stefan N. Willich, Paulus Kirchhof. (2011) Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clinical Research in Cardiology 100:10, 897-905
CrossRef25
D. D. Spragg, H. Calkins. (2011) How do we discover the unknown unknowns? Screening 'Well' patients after catheter ablation for atrial fibrillation. Europace 13:10, 1362-1363
CrossRef26
Daniel Caldeira, Cláudio David, Cristina Sampaio. (2011) Rate vs rhythm control in patients with atrial fibrillation and heart failure: A systematic review and meta-analysis of randomised controlled trials. European Journal of Internal Medicine 22:5, 448-455
CrossRef27
Shujun Gao, Juhaeri Juhaeri, Heather A. Schiappacasse, Andrew T. Koren, Wanju S. Dai. (2011) Evaluation of Dronedarone Use in the US Patient Population Between 2009 and 2010: A Descriptive Study Using a Claims Database. Clinical Therapeutics
CrossRef28
A.J. Workman, G.L. Smith, A.C. Rankin. (2011) Mechanisms of termination and prevention of atrial fibrillation by drug therapy. Pharmacology & Therapeutics 131:2, 221-241
CrossRef29
Anne B Riley, Warren J Manning. (2011) Atrial fibrillation: an epidemic in the elderly. Expert Review of Cardiovascular Therapy 9:8, 1081-1090
CrossRef30
Oleg V. Aslanidi, Moza Al-Owais, Alan P. Benson, Michael Colman, Clifford J. Garratt, Stephen H. Gilbert, John P. Greenwood, Arun V. Holden, Sanjay Kharche, Elizabeth Kinnell, Eleftheria Pervolaraki, Sven Plein, Jonathan Stott, Henggui Zhang. (2011) Virtual tissue engineering of the human atrium: Modelling pharmacological actions on atrial arrhythmogenesis. European Journal of Pharmaceutical Sciences
CrossRef31
Dariusz Kozlowski, Szymon Budrejko, Gregory Y. H. Lip, Dimitri P. Mikhailidis, Jacek Rysz, Grzegorz Raczak, Maciej Banach. (2011) Dronedarone: An overview. Annals of Medicine1-13
CrossRef32
GABOR Z. DURAY, CHRISTIAN TORP-PEDERSEN, STUART J. CONNOLLY, STEFAN H. HOHNLOSER. (2011) Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies. Journal of Cardiovascular Electrophysiology 22:7, 770-776
CrossRef33
ANDREA M. RUSSO. (2011) The Impact of Dronedarone on Lone Atrial Fibrillation: Perhaps Not Such a “Benign” Arrhythmia?. Journal of Cardiovascular Electrophysiology 22:7, 777-780
CrossRef34
Jana Svetlichnaya, Liviu Klein. (2011) Atrial fibrillation in elderly patients with heart failure: convergence of two cardiovascular epidemics in the 21st Century. Expert Review of Cardiovascular Therapy 9:7, 903-912
CrossRef35
Gerald V. Naccarelli. (2011) Post-ATHENA and beyond. Journal of Interventional Cardiac Electrophysiology 31:1, 55-60
CrossRef36
Michele Marzocchi, Federico Lombardi. (2011) Dronedarone for atrial fibrillation therapy. Expert Review of Cardiovascular Therapy 9:6, 675-683
CrossRef37
Alessandro Marinelli, Alessandro Capucci. (2011) Antiarrhythmic drugs for atrial fibrillation. Expert Opinion on Pharmacotherapy 12:8, 1201-1215
CrossRef38
Nikolaos Dagres, Philipp Sommer, Maria Anastasiou-Nana, Gerhard Hindricks. (2011) Treating arrhythmias: an expert opinion. Expert Opinion on Pharmacotherapy 12:9, 1359-1367
CrossRef39
John Camm. (2011) Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits. International Journal of Cardiology
CrossRef40
Kelly M. Smith, Jennifer G. Bekker, Tracy E. Macaulay. (2011) Strategies for the Management of Postoperative Atrial Fibrillation. Orthopedics 34:5, 377-382
CrossRef41
T. Jared Bunch, Bernard J. Gersh. (2011) Rhythm Control Strategies and the Role of Antiarrhythmic Drugs in the Management of Atrial Fibrillation: Focus on Clinical Outcomes. Journal of General Internal Medicine 26:5, 531-537
CrossRef42
Sony Jacob, Omaima A Ali, Victoria Pidlaoan, Apurva O Badheka, Nicholas Z Kerin. (2011) Pharmacotherapy of Atrial Fibrillation: A Pathophysiological Perspective and Review. American Journal of Therapeutics 18:3, 241-260
CrossRef43
Hendrik Bonnemeier, Ralph F. Bosch, Annette Kohlhaußen, Ludger Rosin, Stefan N. Willich, David Pittrow, Wilhelm Kirch, for the MOVE Study Group. (2011) Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Current Medical Research and Opinion 27:5, 995-1003
CrossRef44
Gerald W. Smetana, Jane S. Sillman. (2011) Update in New Medications for Primary Care. Journal of General Internal Medicine 26:4, 427-432
CrossRef45
Roman Bogdan, Heinz Goegelein, Hartmut Ruetten. (2011) Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn-Schmiedeberg's Archives of Pharmacology 383:4, 347-356
CrossRef46
Richard L. Page, Stuart J. Connolly, Harry J.G.M. Crijns, Martin van Eickels, Christophe Gaudin, Christian Torp-Pedersen, Stefan H. Hohnloser. (2011) Rhythm- and Rate-Controlling Effects of Dronedarone in Patients With Atrial Fibrillation (from the ATHENA Trial). The American Journal of Cardiology 107:7, 1019-1022
CrossRef47
T. S. Potpara, G. Y. H. Lip. (2011) Lone atrial fibrillation: what is known and what is to come. International Journal of Clinical Practice 65:4, 446-457
CrossRef48
F. Brigadeau. (2011) Place des antiarythmiques dans les nouvelles recommandations sur la fibrillation atriale. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:197, 7-10
CrossRef49
N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, M. Reynolds. (2011) Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13:3, 329-345
CrossRef50
R. Lemery. (2011) Catheter ablation of paroxysmal atrial fibrillation: long-term follow-up and the inevitability to fibrillate. Europace 13:3, 301-303
CrossRef51
Pasquale Santangeli, Luigi Di Biase, Gemma Pelargonio, J. David Burkhardt, Andrea Natale. (2011) The pharmaceutical pipeline for atrial fibrillation. Annals of Medicine 43:1, 13-32
CrossRef52
JAMES A. REIFFEL. (2011) Atrial Fibrillation: What Have Recent Trials Taught Us Regarding Pharmacologic Management of Rate and Rhythm Control?. Pacing and Clinical Electrophysiology 34:2, 247-259
CrossRef53
A. Fink, G. Z. Duray, S. H. Hohnloser. (2011) A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone. Europace 13:2, 284-285
CrossRef54
T. Barry Levine, Thomas Giles, David Radzik, Jalal K. Ghali. (2011) Effect of Dronedarone on Exercise Capacity and Cardiac Function in Patients With Severe Left Ventricular Dysfunction and Compensated Stable Heart Failure. Cardiovascular Drugs and Therapy
CrossRef55
Juan F. Viles-Gonzalez, Valentin Fuster, Jonathan Halperin, Hugh Calkins, Vivek Y. Reddy. (2011) Rhythm Control for Management of Patients With Atrial Fibrillation: Balancing the Use of Antiarrhythmic Drugs and Catheter Ablation. Clinical Cardiology 34:1, 23-29
CrossRef56
Walid Saliba, Oussama M. Wazni. (2011) Sinus Rhythm Restoration and Treatment Success: Insight From Recent Clinical Trials. Clinical Cardiology 34:1, 12-22
CrossRef57
Xavier Borrás-Pérez, Nekane Murga-Eizagaechevarría. (2011) Novedades en cardiología clínica. La actitud del cardiólogo clínico ante los nuevos fármacos cardiovasculares. Revista Española de Cardiología 64, 73-80
CrossRef58
Razali Omar, Wee Siong Teo, David Foo, Chee Kok Han, Ahmad Nizar Jamaluddin, Lip Ping Low, Tiong Kiam Ong. (2011) Atrial Fibrillation in Singapore and Malaysia: Current Trends and Future Prospects. Journal of Arrhythmia 27:3, 171-185
CrossRef59
L. Samuel Wann, Anne B. Curtis, Craig T. January, Kenneth A. Ellenbogen, James E. Lowe, N.A. Mark Estes, Richard L. Page, Michael D. Ezekowitz, David J. Slotwiner, Warren M. Jackman, William G. Stevenson, Cynthia M. Tracy. (2011) 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). Heart Rhythm 8:1, 157-176
CrossRef60
Sylvia Abadir, Paul Khairy. (2011) Electrophysiology and Adult Congenital Heart Disease: Advances and Options. Progress in Cardiovascular Diseases 53:4, 281-292
CrossRef61
L. Samuel Wann, Anne B. Curtis, Craig T. January, Kenneth A. Ellenbogen, James E. Lowe, N.A. Mark Estes, Richard L. Page, Michael D. Ezekowitz, David J. Slotwiner, Warren M. Jackman, William G. Stevenson, Cynthia M. Tracy, Valentin Fuster, Lars E. Rydén, David S. Cannom, Jean-Yves Le Heuzey, Harry J. Crijns, James E. Lowe, Anne B. Curtis, S. Bertil Olsson, Kenneth A. Ellenbogen, Eric N. Prystowsky, Jonathan L. Halperin, Juan Luis Tamargo, G. Neal Kay, L. Samuel Wann. (2011) 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). Journal of the American College of Cardiology 57:2, 223-242
CrossRef62
A. Finzi. 2011. Positive inotropic drugs and drugs used in dysrhythmias. , 377-395.
CrossRef63
Fabiana Lucà, Mark La Meir, Carmelo Massimiliano Rao, Orlando Parise, Ludovico Vasquez, Rocco Carella, Roberto Lorusso, Benedetto Daniela, Jos Maessen, Gian Franco Gensini, Sandro Gelsomino. (2011) Pharmacological Management of Atrial Fibrillation: One, None, One Hundred Thousand. Cardiology Research and Practice 2011, 1-10
CrossRef64
B.-D. Gonska. (2010) Dronedaron. Herzschrittmachertherapie + Elektrophysiologie 21:4, 244-247
CrossRef65
J.-Y. Le Heuzey. (2010) Prise en charge de la fibrillation atriale, ce qu’il faut savoir sur les anciens et les nouveaux anti-arythmiques. Annales de Cardiologie et d'Angéiologie 59, S24-S27
CrossRef66
Martin Schwaiblmair, Thomas Berghaus, Thomas Haeckel, Theodor Wagner, Wolfgang Scheidt. (2010) Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?. Clinical Research in Cardiology 99:11, 693-700
CrossRef67
B. Pamukcu, G. Y. H. Lip. (2010) Insights from the new European Society of Cardiology guidelines for the medical management of atrial fibrillation. International Journal of Clinical Practice 64:12, 1587-1590
CrossRef68
Jaekyoo Lee, Subhash P. Khanapure, Hwa-Ok Kim, Raj (S. B.) Rajur, Bing Li, John D. Williams, Ramdas Pai, Norton P. Peet. (2010) Efficient Synthesis of a Benzo[ b ]furan Building Block. Synthetic Communications 40:22, 3390-3396
CrossRef69
Mark D. O'Neill, Matthew Wright, Pierre Jaïs, Sebastien Knecht, Isabelle Nault, Seiichiro Matsuo, Shinsuke Miyazaki, Andrej Pernat, Amir Jadidi, Frédéric Sacher, D. Wyn Davies, Jacques Clémenty, Michel Haïssaguerre, Mélèze Hocini. 2010. Treatment of Atrial Arrhythmias in Heart Failure Patients. , 217-234.
CrossRef70
Shailesh C. Shirolkar, Mona Fiuzat, Richard C. Becker. (2010) Dronedarone and vitamin K antagonists: A review of drug-drug interactions. American Heart Journal 160:4, 577-582
CrossRef71
Alexander Burashnikov, Serge Sicouri, José M. Di Diego, Luiz Belardinelli, Charles Antzelevitch. (2010) Synergistic Effect of the Combination of Ranolazine and Dronedarone to Suppress Atrial Fibrillation. Journal of the American College of Cardiology 56:15, 1216-1224
CrossRef72
Arnold Pinter, Paul Dorian. (2010) REVIEW: New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG. Cardiovascular Therapeutics 28:5, 302-310
CrossRef73
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:10, 1360-1420
CrossRef74
Mark Alber Meshil, Deepak Bhakta. (2010) REVIEW: Nonpharmacological Therapies for Atrial Fibrillation. Cardiovascular Therapeutics 28:5, 264-277
CrossRef75
Stuart J. Connolly, Stefan H. Hohnloser. (2010) Dronedarone for Atrial Fibrillation. Journal of the American College of Cardiology 56:16, 1353-1354
CrossRef76
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 31:19, 2369-2429
CrossRef77
Peter J. Hughes, Maisha Kelly Freeman, Frances V. Cohenour, Emily M. Price. (2010) Dronedarone: An Alternative to Amiodarone?. The Consultant Pharmacist 25:9, 555-569
CrossRef78
Ola O Oyetayo, Carrie E Rogers, Prudence O Hofmann. (2010) Dronedarone: A New Antiarrhythmic Agent. Pharmacotherapy 30:9, 904-915
CrossRef79
Alexander Burashnikov, Luiz Belardinelli, Charles Antzelevitch. (2010) Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm 7:9, 1273-1279
CrossRef80
Michael R. Franz, Steve N. Singh. (2010) Amiodarone and dronedarone: The worker bee and the drone?. Heart Rhythm 7:9, 1280-1281
CrossRef81
Halina Frydman, Michael Szarek. (2010) Estimation of overall survival in an ‘illness-death’ model with application to the vertical transmission of HIV-1. Statistics in Medicine 29:19, 2045-2054
CrossRef82
Leif Carlsson, Göran Duker, Ingemar Jacobson. (2010) New pharmacological targets and treatments for atrial fibrillation. Trends in Pharmacological Sciences 31:8, 364-371
CrossRef83
Chee W Khoo, Hoong Sern Lim, Gregory YH Lip. (2010) Dronedarone: NICE enough?. Expert Review of Cardiovascular Therapy 8:8, 1049-1051
CrossRef84
S. H. Hohnloser, H. J. G. M. Crijns, M. van Eickels, C. Gaudin, R. L. Page, C. Torp-Pedersen, S. J. Connolly, . (2010) Dronedarone in patients with congestive heart failure: insights from ATHENA. European Heart Journal 31:14, 1717-1721
CrossRef85
Alessandro Marinelli, Alessandro Rosi, Alessandro Capucci. (2010) Role of sotalol in rhythm control of atrial fibrillation. Therapy 7:4, 391-407
CrossRef86
Edward C Li, John S Esterly, Shaunte Pohl, Shane D Scott, Brian F McBride. (2010) Drug-Induced QT-Interval Prolongation: Considerations for Clinicians. Pharmacotherapy 30:7, 684-701
CrossRef87
Ann C. Garlitski, N. A. Mark Estes. (2010) Emerging therapies for atrial fibrillation: is the paradigm shifting?. Journal of Interventional Cardiac Electrophysiology 28:1, 1-4
CrossRef88
Steven Baroletti, Jennifer Catella, Michael Ehle, Judy W. M. Cheng. (2010) Dronedarone. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:2, 94-101
CrossRef89
JEAN-YVES LE HEUZEY, GAETANO M. DE FERRARI, DAVID RADZIK, MASSIMO SANTINI, JUNREN ZHU, JEAN-MARC DAVY. (2010) A Short-Term, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study. Journal of Cardiovascular Electrophysiology 21:6, 597-605
CrossRef90
S. Ahmed, A. V. Ranchor, H. J. G. M. Crijns, D. J. Van Veldhuisen, I. C. Van Gelder, . (2010) Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation. Europace 12:6, 785-791
CrossRef91
Ashok J. Shah, Xingpeng Liu, Amir S. Jadidi, Michel Haïssaguerre. (2010) Early management of atrial fibrillation: from imaging to drugs to ablation. Nature Reviews Cardiology 7:6, 345-354
CrossRef92
Concepción Moro, Antonio Hernández-Madrid, Roberto Matía. (2010) Non-Antiarrhythmic Drugs to Prevent Atrial Fibrillation. American Journal Cardiovascular Drugs 10:3, 165-173
CrossRef93
Carlos G. Santos-Gallego, Jeremías Bayón, Juan José Badimón. (2010) Thrombi of Different Pathologies: Implications for Diagnosis and Treatment. Current Treatment Options in Cardiovascular Medicine 12:3, 274-291
CrossRef94
Andrew Tinker, Stephen C Harmer. (2010) K + channels in the heart: new insights and therapeutic implications. Expert Review of Clinical Pharmacology 3:3, 305-319
CrossRef95
I. Nault, S. Miyazaki, A. Forclaz, M. Wright, A. Jadidi, P. Jais, M. Hocini, M. Haissaguerre. (2010) Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. European Heart Journal 31:9, 1046-1054
CrossRef96
Bernd-Dieter Gonska. (2010) Atrial fibrillation—rate or rhythm control?. Clinical Research in Cardiology Supplements 5:S1, 11-15
CrossRef97
Christian Torp-Pedersen, Ole Dyg Pedersen, Lars Køber. (2010) Antiarrhythmic Drugs. Journal of the American College of Cardiology 55:15, 1577-1579
CrossRef98
David Singh, Eugenio Cingolani, George A. Diamond, Sanjay Kaul. (2010) Dronedarone for Atrial Fibrillation. Journal of the American College of Cardiology 55:15, 1569-1576
CrossRef99
ERIC N PRYSTOWSKY, JOHN CAMM, GREGORY Y.H. LIP, MAURITS ALLESSIE, JEAN-FRANÇOIS BERGMANN, GÜNTER BREITHARDT, JOSEP BRUGADA, HARRY CRIJNS, PATRICK T. ELLINOR, DANIEL MARK, GERALD NACCARELLI, DOUGLAS PACKER, JUAN TAMARGO. (2010) The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. Journal of Cardiovascular Electrophysiologyno-no
CrossRef100
Marcos Daccarett, Johannes Brachmann, Martin Schmidt. (2010) New concepts in understanding antiarrhythmic effects. Clinical Research in Cardiology Supplements 5:S1, 42-46
CrossRef101
Dobromir Dobrev, Stanley Nattel. (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. The Lancet 375:9721, 1212-1223
CrossRef102
Nadina Stadler, Thorsten Lewalter. (2010) Innovations in drug treatment of atrial fibrillation. Clinical Research in Cardiology Supplements 5:S1, 47-50
CrossRef103
David Singh, Steven Singh. (2010) Emerging drugs for atrial fibrillation. Therapy 7:2, 125-132
CrossRef104
Wilmar M. Wiersinga. (2010) The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches. Heart Failure Reviews 15:2, 121-124
CrossRef105
Prakash C. Deedwania, Joel A. Lardizabal. (2010) Atrial Fibrillation in Heart Failure: A Comprehensive Review. The American Journal of Medicine 123:3, 198-204
CrossRef106
Alexander Burashnikov, Charles Antzelevitch. (2010) New developments in atrial antiarrhythmic drug therapy. Nature Reviews Cardiology 7:3, 139-148
CrossRef107
Jonathan P. Piccini, David F. Kong. (2010) Reply. Journal of the American College of Cardiology 55:10, 1052-1053
CrossRef108
Jonas A. Cooper. (2010) Dronedarone Is Superior to Placebo. Journal of the American College of Cardiology 55:10, 1052
CrossRef109
Thorsten Lewalter. (2010) Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Journal of the American College of Cardiology 55:10, 1051-1052
CrossRef110
&NA;. (2010) Dronedarone: a guide to its use in atrial fibrillation. Drugs & Therapy Perspectives 26:3, 1-5
CrossRef111
Jeremy A. Schafer, Nicole K. Kjesbo, Patrick P. Gleason. (2010) Dronedarone: Current Evidence and Future Questions. Cardiovascular Therapeutics 28:1, 38-47
CrossRef112
Marcus L. Koller, Burghard Schumacher. (2010) Medikamentöse Therapie von Herzrhythmusstörungen. Medizinische Klinik 105:1, 26-40
CrossRef113
Eric N. Prystowsky. (2010) Atrial fibrillation: Dronedarone and amiodarone—the safety versus efficacy debate. Nature Reviews Cardiology 7:1, 5-6
CrossRef114
Miguel Á. Arias, Marta Pachón, Alberto Puchol, Eduardo Castellanos. (2010) Electrofisiología cardiaca y arritmias. Revista Española de Cardiología 63, 61-72
CrossRef115
Janna Cohen-Lehman, Peter Dahl, Sara Danzi, Irwin Klein. (2010) Effects of amiodarone therapy on thyroid function. Nature Reviews Endocrinology 6:1, 34-41
CrossRef116
Jens Seiler, William G. Stevenson. (2010) Atrial Fibrillation in Congestive Heart Failure. Cardiology in Review 18:1, 38-50
CrossRef117
Manuel Martínez-Sellés, Tomás Datino, Óscar Díaz-Castro, Ramón López-Palop. (2010) Actualización en cardiología geriátrica. Revista Española de Cardiología 63, 17-28
CrossRef118
Gabor Z Duray, Joachim R Ehrlich, Stefan H Hohnloser. (2010) Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation. Current Opinion in Cardiology 25:1, 53-58
CrossRef119
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, C. W. Israel, K.-H. Kuck, G. Y.H. Lip, S. Nattel, R. L. Page, U. Ravens, U. Schotten, G. Steinbeck, P. Vardas, A. Waldo, K. Wegscheider, S. Willems, G. Breithardt. (2009) Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. European Heart Journal 30:24, 2969-2980
CrossRef120
Dennis J. Cada, Terri L. Levien, Danial E. Baker. (2009) Formulary Drug Reviews - Dronedarone. Hospital Pharmacy 44:12, 1115-1123
CrossRef121
Silvia A. Eskes, Wilmar M. Wiersinga. (2009) Amiodarone and thyroid. Best Practice & Research Clinical Endocrinology & Metabolism 23:6, 735-751
CrossRef122
&NA;. (2009) Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. Survey of Anesthesiology 53:6, 275-276
CrossRef123
Hessel F. Groenveld, Harry J.G.M. Crijns, Michiel Rienstra, Maarten P. Van den Berg, Dirk J. Van Veldhuisen, Isabelle C. Van Gelder. (2009) Does intensity of rate control influence outcome in persistent atrial fibrillation?. American Heart Journal 158:5, 785-791
CrossRef124
Bramah Singh. (2009) Atrial fibrillation: from ion channels to bedside treatment options. Journal of Electrocardiology 42:6, 660-670
CrossRef125
Richard L. Page, Bashar Hamad, Peter Kirkpatrick. (2009) Dronedarone. Nature Reviews Drug Discovery 8:10, 769-770
CrossRef126
Kenan Yalta, Okan Onur Turgut, Mehmet Birhan Yılmaz, Ahmet Yılmaz, Izzet Tandogan. (2009) Dronedarone: A Promısıng Alternatıve for the Management of Atrıal Fıbrıllatıon. Cardiovascular Drugs and Therapy 23:5, 385-393
CrossRef127
Kapil Kumar, Peter J. Zimetbaum. (2009) New and emerging antiarrhythmic drugs for atrial fibrillation: What may become available to the clinician in the near future. Current Treatment Options in Cardiovascular Medicine 11:5, 373-380
CrossRef128
Danielle Garcia, Angela Cheng-Lai. (2009) Dronedarone. Cardiology in Review 17:5, 230-234
CrossRef129
Paul S. Chan, Brahmajee K. Nallamothu, Hakan Oral. (2009) Amiodarone or Dronedarone for Atrial Fibrillation. Journal of the American College of Cardiology 54:12, 1096-1098
CrossRef130
Jonathan P. Piccini, Vic Hasselblad, Eric D. Peterson, Jeffrey B. Washam, Robert M. Califf, David F. Kong. (2009) Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Journal of the American College of Cardiology 54:12, 1089-1095
CrossRef131
G Morissette, A Ammoury, D Rusu, MC Marguery, R Lodge, PE Poubelle, F Marceau. (2009) Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. British Journal of Pharmacology 157:8, 1531-1540
CrossRef132
Sheridan M. Hoy, Susan J. Keam. (2009) Dronedarone. Drugs 69:12, 1647-1663
CrossRef133
Gregory M. Marcus, Edmund Keung, Melvin M. Scheinman. (2009) The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology 54:9, 777-787
CrossRef134
JAMES A. REIFFEL. (2009) Cardioversion for Atrial Fibrillation: Treatment Options and Advances. Pacing and Clinical Electrophysiology 32:8, 1073-1084
CrossRef135
Dimpi Patel, Andrea Natale, Luigi Di Biase, J David Burkhardt, Yan Wang, Javier E Sanchez, Rodney P Horton, Mohammed Khan. (2009) Catheter ablation for atrial fibrillation: a promising therapy for congestive heart failure. Expert Review of Cardiovascular Therapy 7:7, 779-787
CrossRef136
Alexander Burashnikov, Charles Antzelevitch. (2009) New Pharmacological Strategies for the Treatment of Atrial Fibrillation. Annals of Noninvasive Electrocardiology 14:3, 290-300
CrossRef137
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, C. W. Israel, K.-H. Kuck, G. Y.H. Lip, S. Nattel, R. L. Page, U. Ravens, U. Schotten, G. Steinbeck, P. Vardas, A. Waldo, K. Wegscheider, S. Willems, G. Breithardt. (2009) Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 11:7, 860-885
CrossRef138
Patricia A. Howard. (2009) Cardiovascular Therapeutics - Dronedarone: Emergence of a New Therapeutic Option for the Treatment of Atrial Fibrillation. Hospital Pharmacy 44:7, 562-565
CrossRef139
(2009) Dronedarone in Atrial Fibrillation. New England Journal of Medicine 360:23, 2479-2481
Full Text140
J. Brachmann, A.-M. Sinha. (2009) Dronedarone: Das neue Antiarrhythmikum?. Herzschrittmachertherapie + Elektrophysiologie 20:2, 73-75
CrossRef141
Suresh Krishnamoorthy, Gregory YH Lip. (2009) Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. Expert Review of Cardiovascular Therapy 7:5, 473-481
CrossRef142
Stefan H. Hohnloser. (2009) Nuevas perspectivas farmacológicas en pacientes con fibrilación auricular: el ensayo ATHENA. Revista Española de Cardiología 62:5, 479-481
CrossRef143
Joachim R. Ehrlich, Stanley Nattel. (2009) Novel Approaches for Pharmacological Management of Atrial Fibrillation. Drugs 69:7, 757-774
CrossRef144
Zimetbaum, Peter J., . (2009) Dronedarone for Atrial Fibrillation — An Odyssey. New England Journal of Medicine 360:18, 1811-1813
Full Text145
Wanwarang Wongcharoen, Shih-Ann Chen. (2009) Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation. Expert Review of Cardiovascular Therapy 7:3, 311-322
CrossRef146
Alejandro Macchia, Sergio Varini, Hugo Grancelli, Daniel Nul, Nicolas Laffaye, Daniel Ferrante, Gianni Tognoni, Hernan C. Doval. (2009) The rationale and design of the FORωARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. American Heart Journal 157:3, 423-427
CrossRef147
J. F. Doyle, K. M. Ho. (2009) Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis. Mayo Clinic Proceedings 84:3, 234-242
CrossRef148
Hohnloser, Stefan H., Crijns, Harry J.G.M., van Eickels, Martin, Gaudin, Christophe, Page, Richard L., Torp-Pedersen, Christian, Connolly, Stuart J., . (2009) Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. New England Journal of Medicine 360:7, 668-678
Full Text149
Denis Roy, Mario Talajic, Marc Dubuc, Bernard Thibault, Peter Guerra, Laurent Macle, Paul Khairy. (2009) Atrial fibrillation and congestive heart failure. Current Opinion in Cardiology 24:1, 29-34
CrossRef150
Manuel Martínez-Sellés, Ramón López-Palop, Tomás Datino, Camino Bañuelos. (2009) Actualización en cardiología geriátrica. Revista Española de Cardiología 62, 53-66
CrossRef151
Joachim R Ehrlich, Stanley Nattel. (2009) Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Current Opinion in Cardiology 24:1, 50-55
CrossRef152
T. S. Han, G. R. Williams, M. P. J. Vanderpump. (2009) Benzofuran derivatives and the thyroid. Clinical Endocrinology 70:1, 2-13
CrossRef153
JOHN P. MORROW, JAMES A. REIFFEL. (2009) Drug Therapy for Atrial Fibrillation: What Will Its Role Be in the Era of Increasing Use of Catheter Ablation?. Pacing and Clinical Electrophysiology 32:1, 108-118
CrossRef154
A. Verma. (2008) Alternatives to amiodarone: search for the Holy Grail. Europace 11:4, 402-404
CrossRef155
Jörn Schmitt, Joachim R. Ehrlich, Stefan H. Hohnloser. (2008) New Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation. Herz Kardiovaskuläre Erkrankungen 33:8, 562-567
CrossRef156
Florian Straube, Uwe Dorwarth, Sabine Janko, Ellen Hoffmann. (2008) Frequenzkontrolle versus Rhythmuskontrolle mit und ohne Herzinsuffizienz. Herz Kardiovaskuläre Erkrankungen 33:8, 568-579
CrossRef157
JAMES C. LAUGHLIN, PETER R. KOWEY. (2008) Dronedarone: A New Treatment for Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 19:11, 1220-1226
CrossRef158
Bramah N Singh. (2008) Amiodarone as Paradigm for Developing New Drugs for Atrial Fibrillation. Journal of Cardiovascular Pharmacology 52:4, 300-305
CrossRef159
A. John Camm, Irina Savelieva. (2008) New antiarrhythmic drugs for atrial fibrillation: Focus on dronedarone and vernakalant. Journal of Interventional Cardiac Electrophysiology 23:1, 7-14
CrossRef160
Wilbert S. Aronow. (2008) Treatment of Atrial Fibrillation and Atrial Flutter. Cardiology in Review 16:5, 230-239
CrossRef161
P. Dorian, B. N. Singh. (2008) Upstream therapies to prevent atrial fibrillation. European Heart Journal Supplements 10:Suppl H, H11-H31
CrossRef162
A. J. Camm, J. A. Reiffel. (2008) Defining endpoints in clinical trials on atrial fibrillation. European Heart Journal Supplements 10:Suppl H, H55-H78
CrossRef163
Emily Conway, Simone Musco, Peter R. Kowey. (2008) New Horizons in Antiarrhythmic Therapy: Will Novel Agents Overcome Current Deficits?. The American Journal of Cardiology 102:6, 12H-19H
CrossRef164
Gerald V Naccarelli, Mario D Gonzalez. (2008) Atrial Fibrillation and the Expanding Role of Catheter Ablation: Do Antiarrhythmic Drugs Have a Future?. Journal of Cardiovascular Pharmacology 52:3, 203-209
CrossRef165
H. Volkmann, L. Richter, C. Bergmann. (2008) Pharmakologische Therapie bei Vorhofflimmern – Was leisten moderne Antiarrhythmika wirklich?. Clinical Research in Cardiology Supplements 3:1, 101-106
CrossRef166
Køber, Lars, Torp-Pedersen, Christian, McMurray, John J.V., Gøtzsche, Ole, Lévy, Samuel, Crijns, Harry, Amlie, Jan, Carlsen, Jan, . (2008) Increased Mortality after Dronedarone Therapy for Severe Heart Failure. New England Journal of Medicine 358:25, 2678-2687
Full Text167
Michael J. Mazzini, Kevin M. Monahan. (2008) Pharmacotherapy for atrial arrhythmias: Present and future. Heart Rhythm 5:6, S26-S31
CrossRef168
Mark E. Josephson, Michael R. Rosen, Gordon F. Tomaselli. (2008) The year in arrhythmias 2007: Part II. Heart Rhythm 5:6, 867-871
CrossRef169
Melvin M. Scheinman, Edmund Keung. (2008) The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology 51:21, 2075-2081
CrossRef170
Huai-Sheng Chen, Wen JunMin, Jianping Liu, Wu ShengNan, Huai-Sheng Chen. 2008. Catheter ablation for paroxysmal and persistent atrial fibrillation. .
CrossRef171
C Michael White. (2008) Is dronedarone effective for the prevention of recurrent atrial fibrillation?. Nature Clinical Practice Cardiovascular Medicine 5:3, 136-137
CrossRef172
Noel G. Boyle, Kalyanam Shivkumar. (2008) Atrial fibrillation and congestive heart failure. Current Heart Failure Reports 5:1, 11-15
CrossRef173
ERIC N. PRYSTOWSKY, PIERRE JAÏS, PETER KOWEY, STANLEY NATTEL, JEREMY N. RUSKIN. (2008) Case Studies with the Experts: Management Decisions in Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 19, S1-S12
CrossRef174
(2007) Dronedarone in Atrial Fibrillation. New England Journal of Medicine 357:23, 2403-2405
Full Text175
K. Graf, M. Roser. (2007) Dronedaron. Der Kardiologe 1:4, 253-255
CrossRef176
(2007) Dronedarone successfully maintains sinus rhythm in patients with atrial fibrillation. Nature Clinical Practice Cardiovascular Medicine 4:12, 641-642
CrossRef177
Ezekowitz, Michael D., . (2007) Maintaining Sinus Rhythm — Making Treatment Better Than the Disease. New England Journal of Medicine 357:10, 1039-1041
Full Text178
Steven R. Kayser. (2007) Dronedarone: In Quest of the Ideal Antiarrhythmic Drug. Progress in Cardiovascular Nursing 22:4, 221-224
CrossRef
- Letters
